Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q2 FY23 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Nov 11, 2022
Slide 1: Exchange filing cover letter for Investor Presentation
November 11, 2022 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Fort, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Dear Sir, Please find at
Slide 2: Zydus Lifesciences Limited Earnings Presentation
Zydus Lifesciences Limited Earnings Presentation 11th November, 2022 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Q2 FY23: At a Glance
Q2 FY23: At a Glance Revenues from Highlights of Q2 FY23 R&D Operations* ❑ Ex-COVID related business, total revenues grew 15% yoy. Rs. 41,347 mn Rs. 2,534 mn ❑ India formulations business continued to progress well (up 11% yoy, ex- 10% YoY 6.1% of revenues COVID) with market share gain in key therap
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % * 64.9% 63.4% 65.0% 62.9% 64.3% 40,727 41,347 26,606 37,598 38,638 24,385 25,114 25,634 36,398 23,064 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Total R&D (Rs. mn) and % to Revenue
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional, One-offs and Discontinued ops.(Rs. mn) Organic Capex (Rs. mn) 6,697 6,087 3,100 5,250 5,295 2,800 2,828 5,069 2,668 2,157 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Net Debt/ EBITDA Net Working Capital* (Rs. mn) 53,270 51,21
Slide 7: India Formulations business
India Formulations business Sustained growth driven by robust performance across key therapies Highlights for the quarter India Formulation Sales (Rs. mn) Q2 FY23 Revenue 12,648 Contribution 12,134 11,640 11,251 ▪ The business grew by 11% YoY, ex-COVID opportunities, 10,785 and divested products. ▪
Slide 8: Consumer Wellness
Consumer Wellness Maintained growth momentum Highlights for the quarter Consumer Wellness Sales (Rs. mn) Q2 FY23 Revenue Contribution ▪ Growth during the quarter was led by Glucon-D, Nycil 6,330 6,916 and EverYuth brands.. 3,774 3,822 4,227 ▪ Gross margins were under pressure on account of 11% prici
Slide 9: US Formulations business
US Formulations business Strengthening position by steady new launches Highlights for the quarter US Formulation Sales (Rs. mn) Q2 FY23 Revenue Contribution ▪ Received 15 new product approvals (incl. 2 tentative 17,084 14,734 14,892 15,592 approvals) during the quarter. 14,233 ▪ Launched 10 new prod
Slide 10: Emerging Markets Formulations business
Emerging Markets Formulations business Base business continued to display robust growth Highlights for the quarter EM Formulation Sales (Rs. mn) Q2 FY23 Revenue Contribution ▪ The business grew by 24% YoY, excluding revenue of 3,487 3,155 3,308 COVID related products from the base. 2,914 2,750 ▪ The
Slide 11: Updates on Innovation
Updates on Innovation NCE: Saroglitazar Magnesium • Submitted the results of hepatic impairment studies of the molecule in NASH and normal PBC patients to USFDA. Hepatic impairment studies in Cirrhotic Cholestatic patients is going on which is likely to be completed by the end of FY23. NCE: Desidust
Slide 12: Zydus at a Glance
Zydus at a Glance >$2 bn Global Revenues1 5th Largest generic Co. in US in terms of prescription3 7 R&D Centers For NCE, APIs, Gx formulations, Biosimilars and Vaccines Over Among 1st Revenues from branded Approved product for In 60% of product 50% business (India, EM and Top 3 families marketed in
Slide 13: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q2 Q2 YoY Q1 QoQ H1 H1 YoY Comments for Q2 FY23 Rs. mn FY23 FY22 gr. FY23 gr. FY23 FY22 gr. Total Income from Ops. 41,347 37,598 10.0% 40,727 1.5% 82,074 77,616 5.7% • Adjusted for COVID related sales Gross Contribution (GC) 25,403 23,988 5.9% 25,634 -0.
Slide 14: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q2 Q2 YoY H1 H1 YoY Rs. mn FY23 FY22 gr. % FY23 FY22 gr. % A. On operating transactions (above EBIDTA line) -1,374 -290 -373.7% -2,542 -771 -230.0% a. Included in other operating income -1,294 -263 -392.0% -2,377 -790 -200.9% b. Included in COGS -80 -27 -195.6%
Slide 15: Q2 FY23 Earnings Call Details
Q2 FY23 Earnings Call Details Date: 11th November, 2022, Friday Time: 3:00 PM IST (Indian Standard Time) To join the call Please pre-register by Clicking here or use One tap mobile: +13017158592,,86350467419# or Dial: +91 80 71 279 440/ +91 22 48 798 004 Webinar ID: 863 5046 7419
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-79-71800839 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi C